Novosibirsk manufacturer will increase the production of vaccine against COVID-19 by 7 times

The Novosibirsk company Vector-Bialgam plans to increase the production of the Epivaccorona CORONAVIRUS vaccine by almost seven times from 1.5 million to 10 million doses. Leonid Nikulin, General DIRECTOR of Vector-Bialgam, told TASS about this.

The HEAD of the company explained that the increase in output will be possible after the modernization of production. Start-up and adjustment works should begin in September. The vaccine will be intended to meet the internal needs of RUSSIA. At the same time, foreign partners are also interested in the vaccine.

“No one expected that demand would grow so much. And this is one of the reasons why it was necessary to speed up the modernization. We can say that this demand prompted to do everything faster,” Nikulin said.

The EpiVacCorona coronavirus vaccine was registered on October 13, 2020. It became the second Russian vaccine against covid-19 . Clinical trials of the drug began in early December. The drug entered civilian circulation on January 1, 2021.

"EpiVacCoron" was created on the basis of artificially synthesized short fragments of viral proteins. With their help, the immunity of a vaccinated person must learn to recognize virus cells.

Currently, four coronavirus vaccines have been registered in Russia: Sputnik V and Sputnik Light from the Center. Gamalei, "EpiVakKorona", developed by the Novosibirsk Center "Vector", and "KoviVak" from the Center. Chumakov.